All In MedTech

FDA Clearance Tracker · P150026-S014

HeartLight Catheter, HeartLight X3 Console V2

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 24, 2023

Approved

Time to decision

308 days

Received Apr 22, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150026-S014
Device name
HeartLight Catheter, HeartLight X3 Console V2
Applicant location
Marlborough, MA
Received
Apr 22, 2022
Decided
Feb 24, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150026

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

Approval for changes to the Console of the HeartLight System.

Source documents

Other decisions for Cardiofocus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.